exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087889 RNA Name: hsa-miR-200c-3p RNA Type: miRNA Chromosome: chr12 Starnd: + Coordinate: Start Site(bp): 6963742 End Site(bp): 6963764 External Links: hsa-miR-200c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CHD9 chr16 53055033 53329150 + CTNND1 chr11 57753243 57819546 + FOXP1 chr3 70952817 71583993 - GPR180 chr13 94601857 94634661 + KLF3 chr4 38664197 38701517 + NRBP1 chr2 27427790 27442259 + NRIP1 chr21 14961235 15065936 - PTP4A1 chr6 63521746 63583436 + RBM12 chr20 35648925 35664956 - SLC35B4 chr7 134289332 134316930 - SMAD7 chr18 48919853 48952052 - SRP72 chr4 56467617 56503681 + THAP2 chr12 71664301 71680644 + XPO4 chr13 20777329 20903048 - AC008982.1 chr19 38817471 38840178 - CASD1 chr7 94509219 94557019 + CEBPZ chr2 37201612 37231596 - ECH1 chr19 38815422 38831841 - PSMB2 chr1 35599541 35641526 - SNX5 chr20 17941597 17968980 - SZRD1 chr1 16352575 16398145 + WDR13 chrX 48590042 48608869 + ZNF217 chr20 53567065 53609907 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0001486 chr5 56526672 56527148 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0001358 chr3 169694733 169706147 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC024940.6 chr12 31280422 31280895 - AC092295.2 chr19 36489649 36491040 + AC116913.1 chr15 66488658 66492109 - AF254983.1 chr21 10482738 10605716 + AL049840.4 chr14 103694516 103695050 - LINC00667 chr18 5237826 5290608 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG22 chr18 49814023 49851059 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.